Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a digital biology company industrializing drug discovery, today announced it has entered into a global licensing agreement with Takeda Pharmaceutical ...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...

Recursion announces clinical trial approvals for REC-3565 and REC-4539, targeting B-cell malignancies and small-cell lung cancer. Recursion announced that the UK Medicines and Healthcare Products ...

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Recursion Pharmaceuticals lacks any of the long history of consistent performance that Buffett favors. Nonetheless, it aspires to become a business with characteristics he might like. It'll take a few ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a digital biology™ company leading in the industrialization of drug discovery, today announced its acquisition of Vium, a digital vivarium™ company. Vium’s ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...